Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03758651 · ClinicalTrials.gov registry record

Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

A clinical trial, sponsored by Massachusetts General Hospital.

Completed
Registry status
144
Enrollment target

NCT03758651: Completed study, sponsored by Massachusetts General Hospital.

NCT03758651 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03758651 has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
144 participants
Enrollment target

Study Summary

Williams syndrome (WS) is a rare microdeletion genetic disorder that has a broad phenotype including many endocrine and metabolic abnormalities. Dr. Pober and colleagues at MGH have reported the following findings in adults with WS: abnormal body composition (excess body fat accumulation with a lipedema phenotype), decreased bone mineral density, abnormal glucose tolerance, and reduced lean mass. Despite the high prevalence and potential effect of metabolic abnormalities on the health of persons with WS, their full phenotypic range, potential causal factors (either genetic and/or hormonal) along with their impact on other aspects of health (such as risk of falls and fractures or interaction with emotional behavioral concerns) remain incompletely characterized. The purpose of the current study in a large cohort of subjects with WS is to: collect further information to characterize the timing of onset and distribution of body fat; better characterize hormonal status of WS subjects; and screen for genetic variation using single-nucleotide-polymorphism (SNP) analysis that could elucidate genetic contributors to the lipedema phenotype as well as the other observed metabolic and bone abnormalities.

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2018-10-01
Est. Completion 2023-09-14
Massachusetts General Hospital

2,032 total trials

What the finished NCT03758651 record still lists

NCT03758651 is an observational study that tracks outcomes without assigning an intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT03758651 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03758651 about?

NCT03758651 is a clinical study titled "Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study". Williams syndrome (WS) is a rare microdeletion genetic disorder that has a broad phenotype including many endocrine and metabolic abnormalities. Dr. Pober and colleagues at MGH have reported the following findings in adults with WS: abnormal body composition (excess body fat accumulation with a lipe...

What is the current status of trial NCT03758651?

This trial is currently completed. The enrollment target is 144 participants. The study started on 2018-10-01. Estimated completion is 2023-09-14.

Who is sponsoring clinical trial NCT03758651?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03758651, the US trial registry maintained by the National Library of Medicine. NCT03758651 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.